FDA OK Lifts Critical Therapeutics
Stock quotes in this article:
CRTX
Critical Therapeutics(CRTX Quote) bounded 30% Thursday morning after specialty pharmaceutical company Dey announced the Food and Drug Administration had approved a new drug application (NDA) for the asthma treatment Zyflo CR.
The NDA is for twice-daily, extended-release tablets, also known as zileuton. Critical Therapeutics, a Lexington, Mass. biopharmaceutical company, and Dey, which is affiliated with Germany's Merck KGaA, will co-market the drug according to an agreement they made in March. Zyflo and Zyflo CR are the only FDA-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children age 12 and older, the companies said. Critical Therapeutics was up 76 cents, to $3.43 in morning trading.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,344.84 | 1,095.63 | 2,144.60 | 32.27 |
Oil *
79.28
|
|
UP
34.92
|
UP
4.14
|
UP
6.16
|
UP
0.26
|
10 Yr
3.23%
SPDR Gold
115.65
|
|
+0.34%
|
+0.38%
|
+0.29%
|
+0.81%
|
Data delayed 20 minutes |














